Skip to Content

Pulzium Approval Status

FDA Approved: No
Brand name: Pulzium
Generic name: tedisamil
Company: Solvay Pharmaceuticals
Treatment for: Atrial Flutter, Atrial Fibrillation

Pulzium IV (tedisamil) is a class III anti-arrhythmic drug in the later phase of clinical development for the treatment of recent onset atrial fibrillation or atrial flutter.

Development Status and FDA Approval Process for Pulzium

DateArticle
Dec 13, 2007Solvay Pharmaceuticals, Inc. Responds to Advisory Committee Recommendation for Further Study of Tedisamil to Treat Atrial Fibrillation
Sep 26, 2007Solvay Pharmaceuticals, Inc. Announces FDA Extension of Tedisamil PDUFA Date
Apr 25, 2007Solvay Pharmaceuticals Files Tedisamil, a New CardiometabolicProduct for the Treatment of Atrial Fibrillation and Atrial Flutter

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide